Novel cancer therapy kick starts clinical trials
pharmafile | July 6, 2021 | News story | Manufacturing and Production | oncology
The first patient has been dosed in Phase 1/2 trials investigating a new form of cancer therapy, gamma delta TCR cell therapy, clinical stage company Gadeta has announced.
The therapy, GDT-002, is a cell therapy product utilising specific γδ TCR for the treatment of a wide range of cancers, looking in particular at multiple myeloma (MM) for this trial.
The Phase 1/2 multicentre study is being run in collaboration with the Dana-Farber Cancer Institute, Mass General Brigham Cancer Care with Beth Israel Deaconess Medical Center, evaluating safety, tolerability and preliminary efficacy of GDT-002.
The target recognized by GDT-002 is upregulated in a wide range of liquid and solid tumours, presenting great therapeutic potential. Preclinical studies have shown that GDT-002 selectively kills primary naïve and relapsed/refractory MM cells and has an activity comparable, in MM animal models, to that of BCMA CAR-T. Importantly, a broad spectrum of liquid and solid tumours is recognized by GDT-002.
Dr Marco Londei, Chief Executive Officer of Gadeta, said: “The initiation of our Phase 1/2 trial of GDT-002 and the dosing of our first patient are a transformational milestone for Gadeta in its mission to provide novel treatments to patients with cancer, including MM.
“Despite the successes with CAR-T and related therapies, patients often develop resistance to currently approved treatments. We believe GDT-002 offers potential as a possible new treatment option for patients with multiple myeloma and potentially other liquid and solid cancers.”
In a release Gadeta stated that they were currently working on a pipeline of cell therapies, utilising tumour specific γδ TCRs, with the aim to bring this pipeline of selected γδ TCR-based products to the clinic, with a focus on solid tumours.
Kat Jenkins
Related Content
Curve Therapeutics’ CSO publishes research on HIF inhibition for cancer treatment
Curve Therapeutics has announced that its chief scientific officer, Professor Ali Tavassoli has published research …
Galapagos and BridGene Biosciences enter collaboration for oncology drug discovery
Galapagos NV and BridGene Biosciences have announced that they have entered into a strategic collaboration …
Genentech shares positive results from phase 3 trial for breast cancer treatment
Genentech, a member of the Roche Group, has announced positive results from the phase 3 …
